Intracranial hypertension induced by rofecoxib

Research output: Contribution to journalArticlepeer-review


  • Saiju Jacob
  • Yusuf A Rajabally

Colleges, School and Institutes

External organisations

  • University Hospitals of Leicester NHS Trust


Several secondary causes are implicated in the etiology of idiopathic intracranial hypertension. Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We report a case of intracranial hypertension in a 69-year-old man 3 weeks after the commencement of rofecoxib therapy with reversal of clinical findings on drug withdrawal.


Original languageEnglish
Pages (from-to)75-6
Number of pages2
Issue number1
Publication statusPublished - Jan 2005


  • Aged, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Arthritis, Rheumatoid/drug therapy, Cyclooxygenase Inhibitors/adverse effects, Humans, Intracranial Hypertension/chemically induced, Lactones/adverse effects, Male, Sulfones/adverse effects